Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the Unite...
Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
The study evaluated the cost of baroreflex activation therapy plus guideline directed therapy (BAT + GDT) compared to GDT alone for HF patients with reduced ejection fraction and New York Heart Association Class III or II (with a recent history of III). Baroreflex activation therapy (BAT) is delivered by an implantable device that stimulates the ba...
Alternative Titles
Full title
Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_02911598bf1a41c68d89d4c94277a78b
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_02911598bf1a41c68d89d4c94277a78b
Other Identifiers
ISSN
1471-2261
E-ISSN
1471-2261
DOI
10.1186/s12872-021-01958-y
